Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new research that helps define clinically meaningful improvement in overall health reported by people living with tardive dyskinesia who ...
Neurocrine Biosciences, Inc. announced new research that helps define clinically meaningful improvement in overall health reported by people living with tardive dyskinesia who were treated with ...
Neurocrine Biosciences (NBIX-0.41%) generated $959 million in revenue in Q2 2026, representing an increase of 39% year over ...
On October 7, 2026, Cerevance announced the top-line results of the Phase 3 ARISE trial for the investigational Parkinson's ...
Alongside medical treatment, adopting healthy habits can help you manage tardive dyskinesia. Find out what experts recommend.
Tardive Dyskinesia (TD) doesn’t just change the way the body moves. It also changes the way we view that body, in mirrors, in ...
13d
FDA approves once-daily Parkinson’s pill (Juvmo) built on decades of work by husband-and-wife team
The FDA approved Juvmo, a once-daily tavapadon pill that selectively activates D1 and D5 dopamine receptors, for adults with ...
ALPHA | Overview of Technology◾️What is Neurocrine Biosciences' SciTech?Pharmaceutical technology targeting neurotransmission ...
Mentara Therapeutics has launched as a new neuropsychiatry company backed by SPRIM Global Investments and acquired MTA-304, a Phase 2-ready PDE10A inhibitor, from EuMentis Therapeutics. The compound ...
Mentara Therapeutics, a new neuropsychiatry company backed by SPRIM Global Investments, today launched with the acquisition of EM-221, ...
AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved JUVMO™ (tavapadon) tablets as the first and only selective D1/D5 receptor agonist for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results